Filtering by:
Soft Tissue SarcomaFDA Approves Tazverik (Tazemetostat) for Epithelioid Sarcoma
The US Food and Drug Administration (FDA) has approved Tazverik (tazemetostat) to treat adults and children 16 and older with epithelioid sarcoma, a rare cancer which accounts for less than 1% of all soft tissue sarcomas.
FDA Approves Vitrakvi (Larotrectinib) for Tumors With Certain Genetic Change
For the second time, the US Food and Drug Administration (FDA) has approved a drug to treat tumors with a specific genetic change regardless of the type of cancer. Vitrakvi (larotrectinib) is for adults and children with solid tumors that test positive for NTRK genes, which can help cancerous tumors grow.
Liposarcoma Survivor Shares Story to Inspire Hope
When soft tissue sarcoma survivor Apreal Cloutier first noticed a lump on the back of her thigh in late 2015, she had no idea it might be cancer.
Cancer Facts and Figures: Death Rate Down 25% Since 1991
The death rate from cancer in the US has declined steadily over the past 2 decades, according to annual statistics reporting from the American Cancer Society.
New Cancer Drug Approvals From 2016
In 2016, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
FDA Approves Lartruvo for Soft Tissue Sarcoma
The US Food and Drug Administration (FDA) has approved Lartruvo (olaratumab) for advanced soft tissue sarcoma.
Cancer Survivors: Words of Inspiration
Surviving cancer is a different experience for everyone. But one thing most survivors say is that their life after the cancer is not the same.
Soft Tissue Sarcoma Survivor Becomes World-Class Athlete
When Brazil hosts the Paralympic Games in 2016, J. Dee Marinko wants to be among the competitors. Marinko has been playing for the US Sitting Volleyball team since he lost his foot to cancer in 2009.